Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Identifieur interne : 004D73 ( Ncbi/Merge ); précédent : 004D72; suivant : 004D74Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Auteurs : Robert S. Rosenson [États-Unis] ; Steven Baker [Canada] ; Maciej Banach [Pologne] ; Kenneth M. Borow [États-Unis] ; Lynne T. Braun [États-Unis] ; Eric Bruckert [France] ; Liam R. Brunham [Canada] ; Alberico L. Catapano [Italie] ; Marshall B. Elam [États-Unis] ; G B John Mancini [Canada] ; Patrick M. Moriarty [États-Unis] ; Pamela B. Morris [États-Unis] ; Paul Muntner [États-Unis] ; Kausik K. Ray [Royaume-Uni] ; Erik S. Stroes [Pays-Bas] ; Beth A. Taylor [États-Unis] ; Valerie H. Taylor [Canada] ; Gerald F. Watts [Australie] ; Paul D. Thompson [États-Unis]Source :
- Journal of the American College of Cardiology [ 1558-3597 ] ; 2017.
Descripteurs français
- KwdFr :
- Anticholestérolémiants (effets indésirables), Anticholestérolémiants (usage thérapeutique), Cholestérol (sang), Facteurs de risque, Humains, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (effets indésirables), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Maladies cardiovasculaires (), Maladies cardiovasculaires (sang), Maladies musculaires (), Muscles squelettiques ().
- MESH :
- effets indésirables : Anticholestérolémiants, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- sang : Cholestérol, Maladies cardiovasculaires.
- usage thérapeutique : Anticholestérolémiants, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- Facteurs de risque, Humains, Maladies cardiovasculaires, Maladies musculaires, Muscles squelettiques.
English descriptors
- KwdEn :
- Anticholesteremic Agents (adverse effects), Anticholesteremic Agents (therapeutic use), Cardiovascular Diseases (blood), Cardiovascular Diseases (prevention & control), Cholesterol (blood), Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Muscle, Skeletal (drug effects), Muscular Diseases (chemically induced), Risk Factors.
- MESH :
- chemical , adverse effects : Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- chemical , blood : Cholesterol.
- chemical , therapeutic use : Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- blood : Cardiovascular Diseases.
- chemically induced : Muscular Diseases.
- drug effects : Muscle, Skeletal.
- prevention & control : Cardiovascular Diseases.
- Humans, Risk Factors.
Abstract
Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.
DOI: 10.1016/j.jacc.2017.07.752
PubMed: 28859793
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000519
- to stream PubMed, to step Curation: 000517
- to stream PubMed, to step Checkpoint: 000517
Links to Exploration step
pubmed:28859793Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</title>
<author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Baker, Steven" sort="Baker, Steven" uniqKey="Baker S" first="Steven" last="Baker">Steven Baker</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Banach, Maciej" sort="Banach, Maciej" uniqKey="Banach M" first="Maciej" last="Banach">Maciej Banach</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora</wicri:regionArea>
<wicri:noRegion>Zielona Gora</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Borow, Kenneth M" sort="Borow, Kenneth M" uniqKey="Borow K" first="Kenneth M" last="Borow">Kenneth M. Borow</name>
<affiliation wicri:level="2"><nlm:affiliation>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Braun, Lynne T" sort="Braun, Lynne T" uniqKey="Braun L" first="Lynne T" last="Braun">Lynne T. Braun</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brunham, Liam R" sort="Brunham, Liam R" uniqKey="Brunham L" first="Liam R" last="Brunham">Liam R. Brunham</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Catapano, Alberico L" sort="Catapano, Alberico L" uniqKey="Catapano A" first="Alberico L" last="Catapano">Alberico L. Catapano</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elam, Marshall B" sort="Elam, Marshall B" uniqKey="Elam M" first="Marshall B" last="Elam">Marshall B. Elam</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mancini, G B John" sort="Mancini, G B John" uniqKey="Mancini G" first="G B John" last="Mancini">G B John Mancini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moriarty, Patrick M" sort="Moriarty, Patrick M" uniqKey="Moriarty P" first="Patrick M" last="Moriarty">Patrick M. Moriarty</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morris, Pamela B" sort="Morris, Pamela B" uniqKey="Morris P" first="Pamela B" last="Morris">Pamela B. Morris</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
<wicri:cityArea>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Muntner, Paul" sort="Muntner, Paul" uniqKey="Muntner P" first="Paul" last="Muntner">Paul Muntner</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
<wicri:cityArea>Department of Epidemiology, University of Alabama Birmingham, Birmingham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ray, Kausik K" sort="Ray, Kausik K" uniqKey="Ray K" first="Kausik K" last="Ray">Kausik K. Ray</name>
<affiliation wicri:level="3"><nlm:affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stroes, Erik S" sort="Stroes, Erik S" uniqKey="Stroes E" first="Erik S" last="Stroes">Erik S. Stroes</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Department of Vascular Medicine, AMC, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Beth A" sort="Taylor, Beth A" uniqKey="Taylor B" first="Beth A" last="Taylor">Beth A. Taylor</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taylor, Valerie H" sort="Taylor, Valerie H" uniqKey="Taylor V" first="Valerie H" last="Taylor">Valerie H. Taylor</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.</nlm:affiliation>
<country>Australie</country>
<placeName><region type="state">Australie-Occidentale</region>
</placeName>
<wicri:cityArea>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Thompson, Paul D" sort="Thompson, Paul D" uniqKey="Thompson P" first="Paul D" last="Thompson">Paul D. Thompson</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Division of Cardiology, Hartford Hospital, Hartford</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28859793</idno>
<idno type="pmid">28859793</idno>
<idno type="doi">10.1016/j.jacc.2017.07.752</idno>
<idno type="wicri:Area/PubMed/Corpus">000519</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000519</idno>
<idno type="wicri:Area/PubMed/Curation">000517</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000517</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000517</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000517</idno>
<idno type="wicri:Area/Ncbi/Merge">004D73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</title>
<author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Baker, Steven" sort="Baker, Steven" uniqKey="Baker S" first="Steven" last="Baker">Steven Baker</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Banach, Maciej" sort="Banach, Maciej" uniqKey="Banach M" first="Maciej" last="Banach">Maciej Banach</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora</wicri:regionArea>
<wicri:noRegion>Zielona Gora</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Borow, Kenneth M" sort="Borow, Kenneth M" uniqKey="Borow K" first="Kenneth M" last="Borow">Kenneth M. Borow</name>
<affiliation wicri:level="2"><nlm:affiliation>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Braun, Lynne T" sort="Braun, Lynne T" uniqKey="Braun L" first="Lynne T" last="Braun">Lynne T. Braun</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brunham, Liam R" sort="Brunham, Liam R" uniqKey="Brunham L" first="Liam R" last="Brunham">Liam R. Brunham</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Catapano, Alberico L" sort="Catapano, Alberico L" uniqKey="Catapano A" first="Alberico L" last="Catapano">Alberico L. Catapano</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elam, Marshall B" sort="Elam, Marshall B" uniqKey="Elam M" first="Marshall B" last="Elam">Marshall B. Elam</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mancini, G B John" sort="Mancini, G B John" uniqKey="Mancini G" first="G B John" last="Mancini">G B John Mancini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moriarty, Patrick M" sort="Moriarty, Patrick M" uniqKey="Moriarty P" first="Patrick M" last="Moriarty">Patrick M. Moriarty</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morris, Pamela B" sort="Morris, Pamela B" uniqKey="Morris P" first="Pamela B" last="Morris">Pamela B. Morris</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Sud</region>
</placeName>
<wicri:cityArea>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Muntner, Paul" sort="Muntner, Paul" uniqKey="Muntner P" first="Paul" last="Muntner">Paul Muntner</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
<wicri:cityArea>Department of Epidemiology, University of Alabama Birmingham, Birmingham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ray, Kausik K" sort="Ray, Kausik K" uniqKey="Ray K" first="Kausik K" last="Ray">Kausik K. Ray</name>
<affiliation wicri:level="3"><nlm:affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stroes, Erik S" sort="Stroes, Erik S" uniqKey="Stroes E" first="Erik S" last="Stroes">Erik S. Stroes</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Department of Vascular Medicine, AMC, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Beth A" sort="Taylor, Beth A" uniqKey="Taylor B" first="Beth A" last="Taylor">Beth A. Taylor</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taylor, Valerie H" sort="Taylor, Valerie H" uniqKey="Taylor V" first="Valerie H" last="Taylor">Valerie H. Taylor</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.</nlm:affiliation>
<country>Australie</country>
<placeName><region type="state">Australie-Occidentale</region>
</placeName>
<wicri:cityArea>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Thompson, Paul D" sort="Thompson, Paul D" uniqKey="Thompson P" first="Paul D" last="Thompson">Paul D. Thompson</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Division of Cardiology, Hartford Hospital, Hartford</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the American College of Cardiology</title>
<idno type="eISSN">1558-3597</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticholesteremic Agents (adverse effects)</term>
<term>Anticholesteremic Agents (therapeutic use)</term>
<term>Cardiovascular Diseases (blood)</term>
<term>Cardiovascular Diseases (prevention & control)</term>
<term>Cholesterol (blood)</term>
<term>Humans</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term>
<term>Muscle, Skeletal (drug effects)</term>
<term>Muscular Diseases (chemically induced)</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticholestérolémiants (effets indésirables)</term>
<term>Anticholestérolémiants (usage thérapeutique)</term>
<term>Cholestérol (sang)</term>
<term>Facteurs de risque</term>
<term>Humains</term>
<term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (effets indésirables)</term>
<term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term>
<term>Maladies cardiovasculaires ()</term>
<term>Maladies cardiovasculaires (sang)</term>
<term>Maladies musculaires ()</term>
<term>Muscles squelettiques ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticholesteremic Agents</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cholesterol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticholesteremic Agents</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Muscular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Muscle, Skeletal</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticholestérolémiants</term>
<term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cholestérol</term>
<term>Maladies cardiovasculaires</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticholestérolémiants</term>
<term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term>
<term>Humains</term>
<term>Maladies cardiovasculaires</term>
<term>Maladies musculaires</term>
<term>Muscles squelettiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28859793</PMID>
<DateCreated><Year>2017</Year>
<Month>09</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>70</Volume>
<Issue>10</Issue>
<PubDate><Year>2017</Year>
<Month>Sep</Month>
<Day>05</Day>
</PubDate>
</JournalIssue>
<Title>Journal of the American College of Cardiology</Title>
<ISOAbbreviation>J. Am. Coll. Cardiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</ArticleTitle>
<Pagination><MedlinePgn>1290-1301</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0735-1097(17)38966-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2017.07.752</ELocationID>
<Abstract><AbstractText>Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.</AbstractText>
<CopyrightInformation>Copyright © 2017 American College of Cardiology Foundation. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenson</LastName>
<ForeName>Robert S</ForeName>
<Initials>RS</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baker</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Banach</LastName>
<ForeName>Maciej</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Borow</LastName>
<ForeName>Kenneth M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo><Affiliation>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Braun</LastName>
<ForeName>Lynne T</ForeName>
<Initials>LT</Initials>
<AffiliationInfo><Affiliation>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bruckert</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brunham</LastName>
<ForeName>Liam R</ForeName>
<Initials>LR</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catapano</LastName>
<ForeName>Alberico L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Elam</LastName>
<ForeName>Marshall B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo><Affiliation>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mancini</LastName>
<ForeName>G B John</ForeName>
<Initials>GBJ</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moriarty</LastName>
<ForeName>Patrick M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morris</LastName>
<ForeName>Pamela B</ForeName>
<Initials>PB</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Muntner</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ray</LastName>
<ForeName>Kausik K</ForeName>
<Initials>KK</Initials>
<AffiliationInfo><Affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stroes</LastName>
<ForeName>Erik S</ForeName>
<Initials>ES</Initials>
<AffiliationInfo><Affiliation>Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taylor</LastName>
<ForeName>Beth A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo><Affiliation>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taylor</LastName>
<ForeName>Valerie H</ForeName>
<Initials>VH</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Watts</LastName>
<ForeName>Gerald F</ForeName>
<Initials>GF</Initials>
<AffiliationInfo><Affiliation>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thompson</LastName>
<ForeName>Paul D</ForeName>
<Initials>PD</Initials>
<AffiliationInfo><Affiliation>Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Am Coll Cardiol</MedlineTA>
<NlmUniqueID>8301365</NlmUniqueID>
<ISSNLinking>0735-1097</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber>
<NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009135" MajorTopicYN="N">Muscular Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
<Keyword MajorTopicYN="N">low-density lipoprotein</Keyword>
<Keyword MajorTopicYN="N">myalgia</Keyword>
<Keyword MajorTopicYN="N">myopathy</Keyword>
<Keyword MajorTopicYN="N">statin intolerance</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>05</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>07</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>07</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28859793</ArticleId>
<ArticleId IdType="pii">S0735-1097(17)38966-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.jacc.2017.07.752</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Pologne</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Alabama</li>
<li>Angleterre</li>
<li>Australie-Occidentale</li>
<li>Caroline du Sud</li>
<li>Connecticut</li>
<li>Grand Londres</li>
<li>Hollande-Septentrionale</li>
<li>Illinois</li>
<li>Kansas</li>
<li>Lombardie</li>
<li>Maryland</li>
<li>Ontario</li>
<li>Tennessee</li>
<li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Amsterdam</li>
<li>Hamilton (Ontario)</li>
<li>Londres</li>
<li>Milan</li>
<li>Paris</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université McMaster</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name>
</region>
<name sortKey="Borow, Kenneth M" sort="Borow, Kenneth M" uniqKey="Borow K" first="Kenneth M" last="Borow">Kenneth M. Borow</name>
<name sortKey="Braun, Lynne T" sort="Braun, Lynne T" uniqKey="Braun L" first="Lynne T" last="Braun">Lynne T. Braun</name>
<name sortKey="Elam, Marshall B" sort="Elam, Marshall B" uniqKey="Elam M" first="Marshall B" last="Elam">Marshall B. Elam</name>
<name sortKey="Moriarty, Patrick M" sort="Moriarty, Patrick M" uniqKey="Moriarty P" first="Patrick M" last="Moriarty">Patrick M. Moriarty</name>
<name sortKey="Morris, Pamela B" sort="Morris, Pamela B" uniqKey="Morris P" first="Pamela B" last="Morris">Pamela B. Morris</name>
<name sortKey="Muntner, Paul" sort="Muntner, Paul" uniqKey="Muntner P" first="Paul" last="Muntner">Paul Muntner</name>
<name sortKey="Taylor, Beth A" sort="Taylor, Beth A" uniqKey="Taylor B" first="Beth A" last="Taylor">Beth A. Taylor</name>
<name sortKey="Thompson, Paul D" sort="Thompson, Paul D" uniqKey="Thompson P" first="Paul D" last="Thompson">Paul D. Thompson</name>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Baker, Steven" sort="Baker, Steven" uniqKey="Baker S" first="Steven" last="Baker">Steven Baker</name>
</region>
<name sortKey="Brunham, Liam R" sort="Brunham, Liam R" uniqKey="Brunham L" first="Liam R" last="Brunham">Liam R. Brunham</name>
<name sortKey="Mancini, G B John" sort="Mancini, G B John" uniqKey="Mancini G" first="G B John" last="Mancini">G B John Mancini</name>
<name sortKey="Taylor, Valerie H" sort="Taylor, Valerie H" uniqKey="Taylor V" first="Valerie H" last="Taylor">Valerie H. Taylor</name>
</country>
<country name="Pologne"><noRegion><name sortKey="Banach, Maciej" sort="Banach, Maciej" uniqKey="Banach M" first="Maciej" last="Banach">Maciej Banach</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name>
</region>
</country>
<country name="Italie"><region name="Lombardie"><name sortKey="Catapano, Alberico L" sort="Catapano, Alberico L" uniqKey="Catapano A" first="Alberico L" last="Catapano">Alberico L. Catapano</name>
</region>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Ray, Kausik K" sort="Ray, Kausik K" uniqKey="Ray K" first="Kausik K" last="Ray">Kausik K. Ray</name>
</region>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Stroes, Erik S" sort="Stroes, Erik S" uniqKey="Stroes E" first="Erik S" last="Stroes">Erik S. Stroes</name>
</region>
</country>
<country name="Australie"><region name="Australie-Occidentale"><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004D73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:28859793 |texte= Optimizing Cholesterol Treatment in Patients With Muscle Complaints. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28859793" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |